THTX stock keeps "Buy" rating at Research Capital
Following the company’s fourth quarter results, Research Capital analyst Andre Uddin has maintained his “Buy” rating on Theratechnologies.
Source: cantechletter.com
📰 Andre Uddin News
Andre Uddin News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Andre Uddin. Real-time updates on events, politics, business and more.
MDNA is undervalued, Research Capital says
Following the company’s third quarter results, Research Capital analyst Andre Uddin has kept his “Speculative Buy” rating on Medicenna Therapeutics
Merck Keytruda Andre Uddin Research Capital Society For Neuro Medicenna Therapeutics Medicenna Therapeutics Stock Quote
Source: cantechletter.com
Medexus earns price target raise at Research Capital
Following moves by the company to shore up its balance sheet, Research Capital analyst Andre Uddin is feeling a little more bullish about MDP.
Andre Uddin Medexus Pharmaceuticals Stock Research Capital Medexus Pharmaceuticals Medexus Pharmaceuticals Stock Quote
Source: cantechletter.com
Sernova (TSX:SVA) stock is cheap, Research Capital says
Following the release of new data on a core offering, Research Capital analyst Andre Uddin remains upbeat about the prospects of Sernova.
United States Cynthia Pussinen Andre Uddin American Thyroid Association Research Capital Sernova Stock Quote
Source: cantechletter.com
SVA stock is undervalued, Research Capital says
A management shuffle at Sernova Corp isn’t dampening analyst Andre Uddin’s enthusiasm for the stock..
Source: cantechletter.com
Theratechnologies is a Buy, says Research Capital
Andre Uddin of Research Capital Corp thinks investors will want to own a piece of Theratechnologies going forward, since its pipeline of drug prospects is worth it. Uddin delivered a report on THTX to clients on Wednesday where he reiterated a Buy rating while lowering his target price to $3.50.
Source: cantechletter.com
Knight Therapeutics Inc. (KHTRF) Q3 2022 Earnings Call Transcript
Knight Therapeutics Inc. (OTCPK:KHTRF) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Samira Sakhia - President and CEO Jeff Martens - Global VP of...
Source: seekingalpha.com
Medexus Pharmaceuticals Inc. (MEDXF) Q2 2023 Earnings Call Transcript
Medexus Pharmaceuticals Inc. (OTCQX:MEDXF) Q2 2023 Earnings Conference Call November 9, 2022 08:00 ET Company Participants Victoria Rutherford - Investor Relations, Adelaide Capital Ken...
Source: seekingalpha.com
Knight Therapeutics' (KHTRF) CEO Samira Sakhia on Q2 2022 Results - Earnings Call Transcript
Knight Therapeutics, Inc. (OTCPK:KHTRF) Q2 2022 Earnings Conference Call August 11, 2022, 8:30 am ET Company Participants Samira Sakhia - President & CEO Amal Khouri - CBO Arvind...
Source: seekingalpha.com
Medexus Pharmaceuticals (MEDXF) CEO, Ken d'Entremont on Q4 2022 Results - Earnings Call Transcript
Medexus Pharmaceuticals Inc. (OTCQX:MEDXF) Q4 2022 Earnings Conference Call June 23, 2022 8:00 am ET Company Participants Ken d’Entremont - Chief Executive Officer Marcel Konrad - Chief...
Source: seekingalpha.com